Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.6115
+0.0115 (1.92%)
At close: Apr 16, 2026, 4:00 PM EDT
0.6013
-0.0102 (-1.67%)
After-hours: Apr 16, 2026, 8:00 PM EDT
Kairos Pharma Employees
As of December 31, 2025, Kairos Pharma had 4 total employees, including 1 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,361,750
Market Cap
13.09M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 1 | 3 |
| Dec 31, 2024 | 4 | - | - | 1 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 43 |
| Imunon | 25 |
| BioCardia | 21 |
| Moleculin Biotech | 17 |
| Cellectar Biosciences | 11 |
| Intensity Therapeutics | 7 |
| Cadrenal Therapeutics | 4 |
| Hoth Therapeutics | 3 |
KAPA News
- 1 day ago - Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation - Business Wire
- 6 weeks ago - Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics - Business Wire
- 7 weeks ago - Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics - Business Wire
- 3 months ago - Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference - Business Wire
- 4 months ago - Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer - Business Wire
- 5 months ago - Kairos Pharma Provides Shareholder Update - Business Wire
- 6 months ago - Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting - Business Wire
- 6 months ago - Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025 - Business Wire